-+ 0.00%
-+ 0.00%
-+ 0.00%

Mineralys posts ENDO 2026 lorundrostat biomarker presentation on uncontrolled hypertension

PUBT·06/15/2026 03:37:03
Listen to the news
Mineralys posts ENDO 2026 lorundrostat biomarker presentation on uncontrolled hypertension
  • Mineralys published ENDO 2026 presentation materials on lorundrostat biomarker effects in uncontrolled hypertension, including treatment-resistant hypertension.
  • Pooled analysis across Launch-HTN Phase 3 and Advance-HTN Phase 2b included 1,004 participants; 733 received lorundrostat, 271 received placebo.
  • Week 12 pharmacodynamic data showed RAAS target engagement, including placebo-adjusted renin increases of 59.6% to 76.5%.
  • Angiotensinogen fell 16.4% to 19.9% versus placebo; 106 biomarkers decreased, 85 increased at FDR < 0.05.
  • Lorundrostat reduced 6 of 11 candidate causal incident heart failure risk biomarkers, including NT-proBNP; analysis linked changes to fibrosis and matrix remodeling pathways.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief on June 14, 2026, and is solely responsible for the information contained therein.